{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T10:21:32Z","timestamp":1765275692348,"version":"3.46.0"},"reference-count":91,"publisher":"Mattioli1885","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:p>The underlying mechanisms behind the development of psoriasis have become better understood in recent years. Key factors involved include the heightened reactivity of certain T-cell subsets (Th1 and Th17 cells), as well as dysregulation of regulatory T-cell (T-reg) function. Additionally, the complex interplay between immune cells, skin cells (keratinocytes), and the blood vessel endothelium has been shown to play an important role in the pathogenesis of psoriasis. Investigations have uncovered the impact that epidermal stem cells and their interactions with T cells have in psoriasis. Importantly, malfunctions across diverse stem cell types may constitute a central mechanism underlying the dysregulated inflammatory processes that characterize this condition. Nonetheless, a more thorough investigation of these mechanisms could present an opportunity to devise novel therapeutic approaches. In this publication, we reviewed the evidence regarding the role played by stem cells in the pathogenesis of psoriasis, as well as initial attempts at leveraging stem cells as a treatment modality.<\/jats:p>","DOI":"10.5826\/dpc.1503a5333","type":"journal-article","created":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T13:04:13Z","timestamp":1752757453000},"page":"5333","source":"Crossref","is-referenced-by-count":1,"title":["Stem Cell Therapy\u2014New Approach and Effective Treatment for Psoriasis"],"prefix":"10.5826","volume":"15","author":[{"given":"Hanan","family":"Hassan Ahmed","sequence":"first","affiliation":[{"name":"College of Pharmacy, Alnoor University, Nineveh, Iraq"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed","family":"J. Saadh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Radhwan","family":"Abdul Kareem","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suhas","family":"Ballal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shilpa","family":"Sharma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Guntaj","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G. V. Siva","family":"Prasad","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Waam","family":"Mohammed Taher","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariem","family":"Alwan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahmood","family":"Jasem Jawad","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atheer","family":"Khdyair Hamad","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"27750","published-online":{"date-parts":[[2025,7,31]]},"reference":[{"key":"10.5826\/dpc.1503a5333_ref1","doi-asserted-by":"crossref","unstructured":"Danielsen K, Olsen A, Wilsgaard T, Furberg AS. Is the prevalence of psoriasis increasing? A 30\u2010year follow\u2010up of a population\u2010based cohort. British Journal of Dermatology. 2013;168(6):1303\u20131310. DOI:10.1111\/bjd.12230.","DOI":"10.1111\/bjd.12230"},{"key":"10.5826\/dpc.1503a5333_ref2","doi-asserted-by":"crossref","unstructured":"Parisi R, Symmons DP, Griffiths CE, Ashcroft DM. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. Journal of Investigative Dermatology. 2013;133(2):377\u2013385. DOI:10.1038\/jid.2012.339","DOI":"10.1038\/jid.2012.339"},{"key":"10.5826\/dpc.1503a5333_ref3","doi-asserted-by":"crossref","unstructured":"Singh S, Young P, Armstrong AW. An update on psoriasis and metabolic syndrome: a meta-analysis of observational studies. PloS one. 2017;12(7):e0181039. DOI:10.1371\/journal.pone.0181039","DOI":"10.1371\/journal.pone.0181039"},{"key":"10.5826\/dpc.1503a5333_ref4","doi-asserted-by":"crossref","unstructured":"Singh S, Taylor C, Kornmehl H, Armstrong AW. Psoriasis and suicidality: a systematic review and meta-analysis. Journal of the American Academy of Dermatology. 2017;77(3):425\u2013440. e2. DOI:10.1016\/j.jaad.2017.05.019","DOI":"10.1016\/j.jaad.2017.05.019"},{"key":"10.5826\/dpc.1503a5333_ref5","doi-asserted-by":"crossref","unstructured":"Randa H, Todberg T, Skov L, Larsen LS, Zachariae R. Health-related quality of life in children and adolescents with psoriasis: a systematic review and meta-analysis. Acta dermato-venereologica. 2017;97(5):555\u2013563. DOI:10.2340\/00015555-2600","DOI":"10.2340\/00015555-2600"},{"key":"10.5826\/dpc.1503a5333_ref6","doi-asserted-by":"crossref","unstructured":"Deng Y, Chang C, Lu Q. The inflammatory response in psoriasis: a comprehensive review. Clinical reviews in allergy & immunology. 2016;50:377\u2013389. DOI:10.1007\/s12016-016-8535-x","DOI":"10.1007\/s12016-016-8535-x"},{"key":"10.5826\/dpc.1503a5333_ref7","doi-asserted-by":"crossref","unstructured":"Martin DA, Towne JE, Kricorian G, et al. The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findings. Journal of Investigative Dermatology. 2013;133(1):17\u201326. DOI:10.1038\/jid.2012.194","DOI":"10.1038\/jid.2012.194"},{"key":"10.5826\/dpc.1503a5333_ref8","doi-asserted-by":"crossref","unstructured":"Kamstrup M, Faurschou A, Gniadecki R, Wulf HC. Epidermal stem cells-role in normal, wounded and pathological psoriatic and cancer skin. Current Stem Cell Research & Therapy. 2008;3(2):146\u2013150. DOI:10.2174\/157488808784223087","DOI":"10.2174\/157488808784223087"},{"key":"10.5826\/dpc.1503a5333_ref9","doi-asserted-by":"crossref","unstructured":"BERGSTRESSER PR, Richard Taylor J. Epidermal \u2018turnover time\u2019\u2014a new examination. British Journal of Dermatology. 1977;96(5):503\u2013506. DOI:10.1111\/j.1365-2133.1977.tb07152.x","DOI":"10.1111\/j.1365-2133.1977.tb07152.x"},{"key":"10.5826\/dpc.1503a5333_ref10","doi-asserted-by":"crossref","unstructured":"Zhang H, Hou W, Henrot L, et al. Modelling epidermis homoeostasis and psoriasis pathogenesis. Journal of The Royal Society Interface. 2015;12(103):20141071. DOI:10.1098\/rsif.2014.1071","DOI":"10.1098\/rsif.2014.1071"},{"key":"10.5826\/dpc.1503a5333_ref11","doi-asserted-by":"crossref","unstructured":"Jia H-Y, Shi Y, Luo L-F, et al. Asymmetric stem-cell division ensures sustained keratinocyte hyperproliferation in psoriatic skin lesions. International journal of molecular medicine. 2016;37(2):359\u2013368. DOI:10.3892\/ijmm.2015.2445","DOI":"10.3892\/ijmm.2015.2445"},{"key":"10.5826\/dpc.1503a5333_ref12","doi-asserted-by":"crossref","unstructured":"Franssen ME, Zeeuwen PL, Vierwinden G, van de Kerkhof PC, Schalkwijk J, Van Erp PE. Phenotypical and functional differences in germinative subpopulations derived from normal and psoriatic epidermis. Journal of Investigative Dermatology. 2005;124(2):373\u2013383. DOI:10.1111\/j.0022-202X.2004.23612.x","DOI":"10.1111\/j.0022-202X.2004.23612.x"},{"key":"10.5826\/dpc.1503a5333_ref13","doi-asserted-by":"crossref","unstructured":"Watarai A, Amoh Y, Maejima H, Hamada Y, Katsuoka K. Nestin expression is increased in the suprabasal epidermal layer in psoriasis vulgaris. Acta dermato-venereologica. 2013;93(1)DOI:10.2340\/00015555-1420","DOI":"10.2340\/00015555-1420"},{"key":"10.5826\/dpc.1503a5333_ref14","doi-asserted-by":"crossref","unstructured":"Nograles K, Zaba L, Guttman\u2010Yassky E, et al. Th17 cytokines interleukin (IL)\u201017 and IL\u201022 modulate distinct inflammatory and keratinocyte\u2010response pathways. British Journal of Dermatology. 2008;159(5):1092\u20131102. DOI:10.1111\/j.1365-2133.2008.08769.x","DOI":"10.1111\/j.1365-2133.2008.08769.x"},{"key":"10.5826\/dpc.1503a5333_ref15","doi-asserted-by":"crossref","unstructured":"Zhou C, Kuang M, Tao Y, et al. Nynrin preserves hematopoietic stem cell function by inhibiting the mitochondrial permeability transition pore opening. Cell Stem Cell. 2024;31(9):1359\u20131375. e8. DOI:10.1016\/j.stem.2024.06.007","DOI":"10.1016\/j.stem.2024.06.007"},{"key":"10.5826\/dpc.1503a5333_ref16","doi-asserted-by":"crossref","unstructured":"Saburi E, Abazari MF, Hassannia H, et al. The use of mesenchymal stem cells in the process of treatment and tissue regeneration after recovery in patients with Covid-19. Gene. 2021;777:145471. DOI:10.1016\/j.gene.2021.145471","DOI":"10.1016\/j.gene.2021.145471"},{"key":"10.5826\/dpc.1503a5333_ref17","doi-asserted-by":"crossref","unstructured":"Velier M, Simoncini S, Abellan M, et al. Adipose-derived stem cells from systemic sclerosis patients maintain pro-angiogenic and antifibrotic paracrine effects in vitro. Journal of Clinical Medicine. 2019;8(11):1979. DOI:10.3390\/jcm8111979","DOI":"10.3390\/jcm8111979"},{"key":"10.5826\/dpc.1503a5333_ref18","doi-asserted-by":"crossref","unstructured":"Ryan JM, Barry FP, Murphy JM, Mahon BP. Mesenchymal stem cells avoid allogeneic rejection. Journal of inflammation. 2005;2:1\u201311. DOI:10.1186\/1476-9255-2-8","DOI":"10.1186\/1476-9255-2-8"},{"key":"10.5826\/dpc.1503a5333_ref19","doi-asserted-by":"crossref","unstructured":"Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood. 2005;105(4):1815\u20131822. DOI:10.1182\/blood-2004-04-1559","DOI":"10.1182\/blood-2004-04-1559"},{"key":"10.5826\/dpc.1503a5333_ref20","doi-asserted-by":"crossref","unstructured":"Hu MS, Borrelli MR, Lorenz HP, Longaker MT, Wan DC. Mesenchymal stromal cells and cutaneous wound healing: a comprehensive review of the background, role, and therapeutic potential. Stem cells international. 2018;2018DOI:10.1155\/2018\/6901983","DOI":"10.1155\/2018\/6901983"},{"key":"10.5826\/dpc.1503a5333_ref21","doi-asserted-by":"crossref","unstructured":"Kozlowska U, Krawczenko A, Futoma K, et al. Similarities and differences between mesenchymal stem\/progenitor cells derived from various human tissues. World journal of stem cells. 2019;11(6):347. DOI:10.4252\/wjsc.v11.i6.347","DOI":"10.4252\/wjsc.v11.i6.347"},{"key":"10.5826\/dpc.1503a5333_ref22","doi-asserted-by":"crossref","unstructured":"Ribeiro A, Laranjeira P, Mendes S, et al. Mesenchymal stem cells from umbilical cord matrix, adipose tissue and bone marrow exhibit different capability to suppress peripheral blood B, natural killer and T cells. Stem cell research & therapy. 2013;4:1\u201316. DOI:10.1186\/scrt336","DOI":"10.1186\/scrt336"},{"key":"10.5826\/dpc.1503a5333_ref23","doi-asserted-by":"crossref","unstructured":"Gao F, Chiu S, Motan D, et al. Mesenchymal stem cells and immunomodulation: current status and future prospects. Cell death & disease. 2016;7(1):e2062\u2013e2062. DOI:10.1038\/cddis.2015.327","DOI":"10.1038\/cddis.2015.327"},{"key":"10.5826\/dpc.1503a5333_ref24","doi-asserted-by":"crossref","unstructured":"Song N, Scholtemeijer M, Shah K. Mesenchymal stem cell immunomodulation: mechanisms and therapeutic potential. Trends in pharmacological sciences. 2020;41(9):653\u2013664. DOI:10.1016\/j.tips.2020.06.009","DOI":"10.1016\/j.tips.2020.06.009"},{"key":"10.5826\/dpc.1503a5333_ref25","doi-asserted-by":"crossref","unstructured":"An Y, Zhang Q, Ren Y, Yang S, Zhang Q. BML-111 Modulates and Alleviates p38\/MAPK Signaling Pathway and Th1\/Th2\/Th17 Cytokine Response in Murine Psoriasis-Like Dermatitis. Discovery medicine. 2024;36(189):2026\u20132036. DOI:10.24976\/Discov.Med.202436189.186","DOI":"10.24976\/Discov.Med.202436189.186"},{"key":"10.5826\/dpc.1503a5333_ref26","doi-asserted-by":"crossref","unstructured":"Gao H, Wang L, Lyu Y, et al. The P2X7R\/NLRP3 inflammasome axis suppresses enthesis regeneration through inflammatory and metabolic macrophage-stem cell cross-talk. Science Advances. 2025;11(17):eadr4894. DOI:10.1126\/sciadv.adr4894","DOI":"10.1126\/sciadv.adr4894"},{"key":"10.5826\/dpc.1503a5333_ref27","unstructured":"Saburi E, Saburi A, Ghanei M. Promising role for Gc-MAF in cancer immunotherapy: from bench to bedside. Caspian Journal of Internal Medicine. 2017;8(4):228. DOI:10.22088\/cjim.8.4.228"},{"key":"10.5826\/dpc.1503a5333_ref28","doi-asserted-by":"crossref","unstructured":"J Salgado A, L Reis R, Sousa N, M Gimble J. Adipose tissue derived stem cells secretome: soluble factors and their roles in regenerative medicine. Current Stem Cell Research & Therapy. 2010;5(2):103\u2013110. DOI:10.2174\/157488810791268564","DOI":"10.2174\/157488810791268564"},{"key":"10.5826\/dpc.1503a5333_ref29","doi-asserted-by":"crossref","unstructured":"Ferreira JR, Teixeira GQ, Santos SG, Barbosa MA, Almeida-Porada G, Gon\u00e7alves RM. Mesenchymal stromal cell secretome: influencing therapeutic potential by cellular pre-conditioning. Frontiers in immunology. 2018;9:2837. DOI:10.3389\/fimmu.2018.02837","DOI":"10.3389\/fimmu.2018.02837"},{"key":"10.5826\/dpc.1503a5333_ref30","doi-asserted-by":"crossref","unstructured":"Zuk PA, Zhu M, Mizuno H, et al. Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue engineering. 2001;7(2):211\u2013228. DOI:10.1089\/107632701300062859","DOI":"10.1089\/107632701300062859"},{"key":"10.5826\/dpc.1503a5333_ref31","doi-asserted-by":"crossref","unstructured":"Mizuno H, Tobita M, Uysal AC. Concise review: adipose\u2010derived stem cells as a novel tool for future regenerative medicine. Stem cells. 2012;30(5):804\u2013810. DOI:10.1002\/stem.1076","DOI":"10.1002\/stem.1076"},{"key":"10.5826\/dpc.1503a5333_ref32","doi-asserted-by":"crossref","unstructured":"Schneider S, Unger M, Van Griensven M, Balmayor ER. Adipose-derived mesenchymal stem cells from liposuction and resected fat are feasible sources for regenerative medicine. European journal of medical research. 2017;22:1\u201311. DOI:10.1186\/s40001-017-0258-9","DOI":"10.1186\/s40001-017-0258-9"},{"key":"10.5826\/dpc.1503a5333_ref33","doi-asserted-by":"crossref","unstructured":"Patrikoski M, Mannerstr\u00f6m B, Miettinen S. Perspectives for clinical translation of adipose stromal\/stem cells. Stem cells international. 2019;2019DOI:10.1155\/2019\/5858247","DOI":"10.1155\/2019\/5858247"},{"key":"10.5826\/dpc.1503a5333_ref34","doi-asserted-by":"crossref","unstructured":"Izadpanah R, Kaushal D, Kriedt C, et al. Long-term in vitro expansion alters the biology of adult mesenchymal stem cells. Cancer research. 2008;68(11):4229\u20134238. DOI:10.1158\/0008-5472.CAN-07-5272","DOI":"10.1158\/0008-5472.CAN-07-5272"},{"key":"10.5826\/dpc.1503a5333_ref35","doi-asserted-by":"crossref","unstructured":"Kern S, Eichler H, Stoeve J, Kl\u00fcter H, Bieback K. Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue. Stem cells. 2006;24(5):1294\u20131301. DOI:10.1634\/stemcells.2005-0342","DOI":"10.1634\/stemcells.2005-0342"},{"key":"10.5826\/dpc.1503a5333_ref36","doi-asserted-by":"crossref","unstructured":"Chen Y, Yu Q, Hu Y, Shi Y. Current research and use of mesenchymal stem cells in the therapy of autoimmune diseases. Current Stem Cell Research & Therapy. 2019;14(7):579\u2013582. DOI:10.2174\/1574888X14666190429141421","DOI":"10.2174\/1574888X14666190429141421"},{"key":"10.5826\/dpc.1503a5333_ref37","doi-asserted-by":"crossref","unstructured":"Abedi M, Alavi-Moghadam S, Payab M, et al. Mesenchymal stem cell as a novel approach to systemic sclerosis; current status and future perspectives. Cell Regeneration. 2020;9:1\u201319. DOI:10.1186\/s13619-020-00058-0","DOI":"10.1186\/s13619-020-00058-0"},{"key":"10.5826\/dpc.1503a5333_ref38","doi-asserted-by":"crossref","unstructured":"Bateman ME, Strong AL, Gimble JM, Bunnell BA. Concise review: using fat to fight disease: a systematic review of nonhomologous adipose-derived stromal\/stem cell therapies. Stem cells. 2018;36(9):1311\u20131328. DOI:10.1002\/stem.2847","DOI":"10.1002\/stem.2847"},{"key":"10.5826\/dpc.1503a5333_ref39","doi-asserted-by":"crossref","unstructured":"\u00c1lvaro-Gracia JM, Jover JA, Garc\u00eda-Vicu\u00f1a R, et al. Intravenous administration of expanded allogeneic adipose-derived mesenchymal stem cells in refractory rheumatoid arthritis (Cx611): results of a multicentre, dose escalation, randomised, single-blind, placebo-controlled phase Ib\/IIa clinical trial. Annals of the rheumatic diseases. 2017;76(1):196\u2013202. DOI:10.1136\/annrheumdis-2015-208918","DOI":"10.1136\/annrheumdis-2015-208918"},{"key":"10.5826\/dpc.1503a5333_ref40","doi-asserted-by":"crossref","unstructured":"Zhou T, Li H-Y, Liao C, Lin W, Lin S. Clinical efficacy and safety of mesenchymal stem cells for systemic lupus erythematosus. Stem cells international. 2020;2020DOI:10.1155\/2020\/6518508","DOI":"10.1155\/2020\/6518508"},{"key":"10.5826\/dpc.1503a5333_ref41","doi-asserted-by":"crossref","unstructured":"Wang L, Zhu C-y, Ma D-x, et al. Efficacy and safety of mesenchymal stromal cells for the prophylaxis of chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: a meta-analysis of randomized controlled trials. Annals of Hematology. 2018;97:1941\u20131950. DOI:10.1007\/s00277-018-3384-8","DOI":"10.1007\/s00277-018-3384-8"},{"key":"10.5826\/dpc.1503a5333_ref42","doi-asserted-by":"crossref","unstructured":"Lalu MM, McIntyre L, Pugliese C, et al. Safe ty of cell therapy with mesenchymal stromal cells (safecell): A systematic review and meta-analysis of clinical trials. PloS one. 2012;7(10):e47559. DOI:10.1371\/journal.pone.0047559","DOI":"10.1371\/journal.pone.0047559"},{"key":"10.5826\/dpc.1503a5333_ref43","doi-asserted-by":"crossref","unstructured":"Petrou P, Kassis I, Levin N, et al. Beneficial effects of autologous mesenchymal stem cell transplantation in active progressive multiple sclerosis. Brain. 2020;143(12):3574\u20133588. DOI:10.1093\/brain\/awaa333","DOI":"10.1093\/brain\/awaa333"},{"key":"10.5826\/dpc.1503a5333_ref44","doi-asserted-by":"crossref","unstructured":"Cao Y, Ding Z, Han C, Shi H, Cui L, Lin R. Efficacy of mesenchymal stromal cells for fistula treatment of Crohn\u2019s disease: a systematic review and meta-analysis. Digestive diseases and sciences. 2017;62:851\u2013860. DOI:10.1007\/s10620-017-4453-x","DOI":"10.1007\/s10620-017-4453-x"},{"key":"10.5826\/dpc.1503a5333_ref45","doi-asserted-by":"crossref","unstructured":"William TT, Pendleton JD, Beyer WM, Egalka MC, Guinan EC. Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. Transplantation. 2003;75(3):389\u2013397. DOI:10.1097\/01.TP.0000045055.63901.A9","DOI":"10.1097\/01.TP.0000045055.63901.A9"},{"key":"10.5826\/dpc.1503a5333_ref46","doi-asserted-by":"crossref","unstructured":"Beyth S, Borovsky Z, Mevorach D, et al. Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness. Blood. 2005;105(5):2214\u20132219. DOI:10.1182\/blood-2004-07-2921","DOI":"10.1182\/blood-2004-07-2921"},{"key":"10.5826\/dpc.1503a5333_ref47","doi-asserted-by":"crossref","unstructured":"Nussbaum L, Chen Y, Ogg G. Role of regulatory T cells in psoriasis pathogenesis and treatment. British Journal of Dermatology. 2021;184(1):14\u201324. DOI:10.1111\/bjd.19380","DOI":"10.1111\/bjd.19380"},{"key":"10.5826\/dpc.1503a5333_ref48","doi-asserted-by":"crossref","unstructured":"Cordiali-Fei P, Bianchi L, Bonifati C, et al. Immunologic biomarkers for clinical and therapeutic management of psoriasis. Mediators of Inflammation. 2014;2014DOI:10.1155\/2014\/236060","DOI":"10.1155\/2014\/236060"},{"key":"10.5826\/dpc.1503a5333_ref49","doi-asserted-by":"crossref","unstructured":"Diluvio L, Romiti M, Angelini F, et al. Infliximab therapy induces increased polyclonality of CD4+ CD25+ regulatory T cells in psoriasis. British Journal of Dermatology. 2010;162(4):895\u2013897. DOI:10.1111\/j.1365-2133.2010.09650.x","DOI":"10.1111\/j.1365-2133.2010.09650.x"},{"key":"10.5826\/dpc.1503a5333_ref50","doi-asserted-by":"crossref","unstructured":"Ma HL, Napierata L, Stedman N, et al. Tumor necrosis factor \u03b1 blockade exacerbates murine psoriasis\u2010like disease by enhancing Th17 function and decreasing expansion of Treg cells. Arthritis & Rheumatism: Official Journal of the American College of Rheumatology. 2010;62(2):430\u2013440. DOI:10.1002\/art.27203","DOI":"10.1002\/art.27203"},{"key":"10.5826\/dpc.1503a5333_ref51","doi-asserted-by":"crossref","unstructured":"Yang J, Zhu J, Lu S, Qin H, Zhou W. Transdermal psoriasis treatment inspired by tumor microenvironment-mediated immunomodulation and advanced by exosomal engineering. Journal of Controlled Release. 2025;382:113664. DOI:10.1016\/j.jconrel.2025.113664","DOI":"10.1016\/j.jconrel.2025.113664"},{"key":"10.5826\/dpc.1503a5333_ref52","doi-asserted-by":"crossref","unstructured":"Shu M, Fan Z, Huang B, Wang C. Retrospective analysis of clinical features of pembrolizumab induced psoriasis. Investigational New Drugs. 2025:1\u20136. DOI:10.1007\/s10637-025-01536-5","DOI":"10.1007\/s10637-025-01536-5"},{"key":"10.5826\/dpc.1503a5333_ref53","doi-asserted-by":"crossref","unstructured":"Zhao S, Sun W, Sun J, Peng L, Wang C. Clinical features, treatment, and outcomes of nivolumab induced psoriasis. Investigational New Drugs. 2025;43(1):42\u201349. DOI:10.1007\/s10637-024-01494-4","DOI":"10.1007\/s10637-024-01494-4"},{"key":"10.5826\/dpc.1503a5333_ref54","doi-asserted-by":"crossref","unstructured":"Kashif S, Al-Mani SY, Almani NY. A Rare Psoriasis Drug Eruption Induced by Levetiracetam: A Case Study from Saudi Arabia. International Journal of Pharmacology. 2024;20(4):704\u2013708. DOI:10.3923\/ijp.2024.704.708","DOI":"10.3923\/ijp.2024.704.708"},{"key":"10.5826\/dpc.1503a5333_ref55","doi-asserted-by":"crossref","unstructured":"Atabati H, Esmaeili SA, Saburi E, et al. Probiotics with ameliorating effects on the severity of skin inflammation in psoriasis: Evidence from experimental and clinical studies. Journal of cellular physiology. 2020;235(12):8925\u20138937. DOI:10.1002\/jcp.29737","DOI":"10.1002\/jcp.29737"},{"key":"10.5826\/dpc.1503a5333_ref56","doi-asserted-by":"crossref","unstructured":"Erichsen C, Jensen P, Kofoed K. Biologic therapies targeting the interleukin (IL)-23\/IL-17 immune axis for the treatment of moderate-to-severe plaque psoriasis: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2020;34(1):30\u201338. DOI:10.1111\/jdv.15879","DOI":"10.1111\/jdv.15879"},{"key":"10.5826\/dpc.1503a5333_ref57","doi-asserted-by":"crossref","unstructured":"Rosenzwajg M, Lorenzon R, Cacoub P, et al. Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial. Annals of the rheumatic diseases. 2019;78(2):209\u2013217. DOI:10.1136\/annrheumdis-2018-214229","DOI":"10.1136\/annrheumdis-2018-214229"},{"key":"10.5826\/dpc.1503a5333_ref58","doi-asserted-by":"crossref","unstructured":"Bovenschen HJ, Van De Kerkhof PC, Van Erp PE, Woestenenk R, Joosten I, Koenen HJ. Foxp3+ regulatory T cells of psoriasis patients easily differentiate into IL-17A-producing cells and are found in lesional skin. Journal of Investigative Dermatology. 2011;131(9):1853\u20131860. DOI:10.1038\/jid.2011.139","DOI":"10.1038\/jid.2011.139"},{"key":"10.5826\/dpc.1503a5333_ref59","doi-asserted-by":"crossref","unstructured":"Bluestone JA, Tang Q. Treg cells\u2014the next frontier of cell therapy. Science. 2018;362(6411):154\u2013155. DOI:10.1126\/science.aau2688","DOI":"10.1126\/science.aau2688"},{"key":"10.5826\/dpc.1503a5333_ref60","doi-asserted-by":"crossref","unstructured":"Adkins D, Abidi M, Brown R, et al. Resolution of psoriasis after allogeneic bone marrow transplantation for chronic myelogenous leukemia: late complications of therapy. Bone marrow transplantation. 2000;26(11):1239\u20131241. DOI:10.1038\/sj.bmt.1702703","DOI":"10.1038\/sj.bmt.1702703"},{"key":"10.5826\/dpc.1503a5333_ref61","doi-asserted-by":"crossref","unstructured":"Snowden J, Heaton D. Development of psoriasis after syngeneic bone marrow transplant from psoriatic donor: further evidence for adoptive autoimmunity. British Journal of Dermatology. 1997;137(1):130\u2013132. DOI:10.1046\/j.1365-2133.1997.17821869.x","DOI":"10.1111\/j.1365-2133.1997.tb03715.x"},{"key":"10.5826\/dpc.1503a5333_ref62","doi-asserted-by":"crossref","unstructured":"Zhang K, Li X, Yin G, Liu Y, Tang X. Functional characterization of T cells differentiated in vitro from bone marrow\u2010derived CD34+ cells of psoriatic patients with family history. Experimental Dermatology. 2010;19(8):e128\u2013e135. DOI:10.1111\/j.1600-0625.2009.01016.x","DOI":"10.1111\/j.1600-0625.2009.01016.x"},{"key":"10.5826\/dpc.1503a5333_ref63","doi-asserted-by":"crossref","unstructured":"Yang L, Li B, Dang E, Jin L, Fan X, Wang G. Impaired function of regulatory T cells in patients with psoriasis is mediated by phosphorylation of STAT3. Journal of dermatological science. 2016;81(2):85\u201392. DOI:10.1016\/j.jdermsci.2015.11.007","DOI":"10.1016\/j.jdermsci.2015.11.007"},{"key":"10.5826\/dpc.1503a5333_ref64","doi-asserted-by":"crossref","unstructured":"Terras S, Gambichler T, Moritz RK, Altmeyer P, Lambert J. Immunohistochemical analysis of FOXP 3+ regulatory T cells in healthy human skin and autoimmune dermatoses. International journal of dermatology. 2014;53(3):294\u2013299. DOI:10.1111\/j.1365-4632.2012.05808.x","DOI":"10.1111\/j.1365-4632.2012.05808.x"},{"key":"10.5826\/dpc.1503a5333_ref65","doi-asserted-by":"crossref","unstructured":"Soler DC, Sugiyama H, Young AB, Massari JV, McCormick TS, Cooper KD. Psoriasis patients exhibit impairment of the high potency CCR5+ T regulatory cell subset. Clinical Immunology. 2013;149(1):111\u2013118. DOI:10.1016\/j.clim.2013.06.007","DOI":"10.1016\/j.clim.2013.06.007"},{"key":"10.5826\/dpc.1503a5333_ref66","doi-asserted-by":"crossref","unstructured":"Zhang K, Li X, Yin G, Liu Y, Niu X, Hou R. Functional characterization of CD4+ CD25+ regulatory T cells differentiated in vitro from bone marrow\u2010derived haematopoietic cells of psoriasis patients with a family history of the disorder. British Journal of Dermatology. 2008;158(2):298\u2013305. DOI:10.1111\/j.1365-2133.2007.08359.x","DOI":"10.1111\/j.1365-2133.2007.08359.x"},{"key":"10.5826\/dpc.1503a5333_ref67","doi-asserted-by":"crossref","unstructured":"Eedy D, Burrows D, Bridges J, Jones F. Clearance of severe psoriasis after allogenic bone marrow transplantation. BMJ: British Medical Journal. 1990;300(6729):908. DOI:10.1136\/bmj.300.6729.908","DOI":"10.1136\/bmj.300.6729.893"},{"key":"10.5826\/dpc.1503a5333_ref68","doi-asserted-by":"crossref","unstructured":"Woods A, Mant M. Amelioration of severe psoriasis with psoriatic arthritis for 20 years after allogeneic haematopoietic stem cell transplantation. Annals of the rheumatic diseases. 2006;65(5):697\u2013697. DOI:10.1136\/ard.2005.039479","DOI":"10.1136\/ard.2005.039479"},{"key":"10.5826\/dpc.1503a5333_ref69","doi-asserted-by":"crossref","unstructured":"Masszi T, Farkas A, Remenyi P, et al. Ten-year remission of psoriasis after allogeneic but not autologous bone marrow transplantation. Dermatology. 2006;212(1):88. DOI:10.1159\/000089032","DOI":"10.1159\/000089032"},{"key":"10.5826\/dpc.1503a5333_ref70","doi-asserted-by":"crossref","unstructured":"Kaffenberger BH, Wong HK, Jarjour W, Andritsos LA. Remission of psoriasis after allogeneic, but not autologous, hematopoietic stem-cell transplantation. Journal of the American Academy of Dermatology. 2013;68(3):489\u2013492. DOI:10.1016\/j.jaad.2012.08.021","DOI":"10.1016\/j.jaad.2012.08.021"},{"key":"10.5826\/dpc.1503a5333_ref71","doi-asserted-by":"crossref","unstructured":"Jowitt S, Yin J. Psoriasis and bone marrow transplantation. BMJ: British Medical Journal. 1990;300(6736):1398. DOI:10.1136\/bmj.300.6736.1398-c","DOI":"10.1136\/bmj.300.6736.1398-c"},{"key":"10.5826\/dpc.1503a5333_ref72","unstructured":"Yin J, Jowitt S. Resolution of immune-mediated diseases following allogeneic bone marrow transplantation for leukaemia. Bone marrow transplantation. 1992;9(1):31\u201333."},{"key":"10.5826\/dpc.1503a5333_ref73","unstructured":"Yokota A, Hukazawa M, Nakaseko C, et al. Resolution of psoriasis vulgaris following allogeneic bone marrow transplantation for aplastic anemia. [Rinsho Ketsueki] The Japanese Journal of Clinical Hematology. 1996;37(1):35\u201339."},{"key":"10.5826\/dpc.1503a5333_ref74","doi-asserted-by":"crossref","unstructured":"Kishimoto Y, Yamamoto Y, Ito T, et al. Transfer of autoimmune thyroiditis and resolution of palmoplantar pustular psoriasis following allogeneic bone marrow transplantation. Bone marrow transplantation. 1997;19(10):1041\u20131043. DOI:10.1038\/sj.bmt.1700789","DOI":"10.1038\/sj.bmt.1700789"},{"key":"10.5826\/dpc.1503a5333_ref75","doi-asserted-by":"crossref","unstructured":"Snowden JA, Kearney P, Kearney A, et al. Long\u2010term outcome of autoimmune disease following allogeneic bone marrow transplantation. Arthritis & Rheumatism: Official Journal of the American College of Rheumatology. 1998;41(3):453\u2013459. DOI:10.1002\/1529-0131(199803)41","DOI":"10.1002\/1529-0131(199803)41:3<453::AID-ART11>3.3.CO;2-R"},{"key":"10.5826\/dpc.1503a5333_ref76","doi-asserted-by":"crossref","unstructured":"Slavin S, Nagler A, Varadi G, Or R. Graft vs autoimmunity following allogeneic non-myeloablative blood stem cell transplantation in a patient with chronic myelogenous leukemia and severe systemic psoriasis and psoriatic polyarthritis. Experimental Hematology. 2000;28(7):853\u2013857. DOI:10.1016\/s0301-472x(00)00172-7","DOI":"10.1016\/S0301-472X(00)00511-7"},{"key":"10.5826\/dpc.1503a5333_ref77","doi-asserted-by":"crossref","unstructured":"Chakrabarti S, Handa SK, Bryon RJ, Griffiths MJ, Milligan DW. Will mixed chimerism cure autoimmune diseases after a nonmyeloablative stem cell transplant? Transplantation. 2001;72(2):340\u2013342. DOI:10.1097\/00007890-200107270-00032","DOI":"10.1097\/00007890-200107270-00032"},{"key":"10.5826\/dpc.1503a5333_ref78","doi-asserted-by":"crossref","unstructured":"Kanamori H, Tanaka M, Kawaguchi H, et al. Resolution of psoriasis following allogeneic bone marrow transplantation for chronic myelogenous leukemia: case report and review of the literature. American journal of hematology. 2002;71(1):41\u201344. DOI:10.1002\/ajh.10169","DOI":"10.1002\/ajh.10169"},{"key":"10.5826\/dpc.1503a5333_ref79","doi-asserted-by":"crossref","unstructured":"Kojima R, Kami M, Kim S, et al. Induction of graft-versus-autoimmune (GVA) disease effect against refractory psoriasis by complete donor-type chimerism and graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Bone marrow transplantation. 2003;32(4):439\u2013442. DOI:10.1038\/sj.bmt.1704146","DOI":"10.1038\/sj.bmt.1704146"},{"key":"10.5826\/dpc.1503a5333_ref80","doi-asserted-by":"crossref","unstructured":"Ciurea SO, Hansrivijit P, Ciurea AM, et al. Curative potential of hematopoietic stem cell transplantation for advanced psoriasis. American journal of hematology. 2019;94(6):E176\u2013E180. DOI:10.1002\/ajh.25470","DOI":"10.1002\/ajh.25470"},{"key":"10.5826\/dpc.1503a5333_ref81","doi-asserted-by":"crossref","unstructured":"Cooley HM, Snowden JA, Grigg AP, Wicks IP. Outcome of rheumatoid arthritis and psoriasis following autologous stem cell transplantation for hematologic malignancy. Arthritis & Rheumatism: Official Journal of the American College of Rheumatology. 1997;40(9):1712\u20131715. DOI:10.1002\/art.1780400923","DOI":"10.1002\/art.1780400923"},{"key":"10.5826\/dpc.1503a5333_ref82","doi-asserted-by":"crossref","unstructured":"Mohren M, Daikeler T, Benz D, G\u00fcnaydin I, Kanz L, K\u00f6tter I. Myeloablative immunosuppressive treatment with autologous haematopoietic stem cell transplantation in a patient with psoriatic arthropathy and monoclonal gammopathy of undetermined significance. Annals of the rheumatic diseases. 2004;63(4):466\u2013467. DOI:10.1136\/ard.2003.010702","DOI":"10.1136\/ard.2003.010702"},{"key":"10.5826\/dpc.1503a5333_ref83","doi-asserted-by":"crossref","unstructured":"Braiteh F, Hymes SR, Giralt SA, Jones R. Complete remission of psoriasis after autologous hematopoietic stem-cell transplantation for multiple myeloma. Journal of clinical oncology. 2008;26(27):4511\u20134513. DOI:10.1200\/JCO.2008.17.6560","DOI":"10.1200\/JCO.2008.17.6560"},{"key":"10.5826\/dpc.1503a5333_ref84","doi-asserted-by":"crossref","unstructured":"Held K, Rahmetulla R, Loew T, Radhi M. Complete resolution of guttate psoriasis following autologous SCT for Ewing\u2019s sarcoma in a pediatric patient. Bone marrow transplantation. 2012;47(12):1585\u20131586. DOI:10.1038\/bmt.2012.68","DOI":"10.1038\/bmt.2012.68"},{"key":"10.5826\/dpc.1503a5333_ref85","unstructured":"Sung SM, Kimball AB. Remission of psoriasis 13 years after autologous stem cell transplant. Cutis. 2015;95(6):E7\u2013E8."},{"key":"10.5826\/dpc.1503a5333_ref86","doi-asserted-by":"crossref","unstructured":"Azevedo A, Gon\u00e7alves C, Selores M, Torres T. Remission of psoriasis after autologous stem cell transplantation-until when? European Journal of Dermatology. 2017;27(1):74\u201375. DOI:10.1684\/ejd.2016.2893","DOI":"10.1684\/ejd.2016.2893"},{"key":"10.5826\/dpc.1503a5333_ref87","doi-asserted-by":"crossref","unstructured":"Chen W, Ren G, Zuo K, Huang X. Complete remission of both immunoglobulin light chain amyloidosis and psoriasis after autologous hematopoietic stem cell transplantation: A case report. Medicine. 2018;97(50):e13589. DOI:10.1097\/MD.0000000000013589","DOI":"10.1097\/MD.0000000000013589"},{"key":"10.5826\/dpc.1503a5333_ref88","doi-asserted-by":"crossref","unstructured":"Chen H, Niu J-W, Ning H-M, et al. Treatment of psoriasis with mesenchymal stem cells. The American journal of medicine. 2016;129(3):e13\u2013e14. DOI:10.1016\/j.amjmed.2015.11.001","DOI":"10.1016\/j.amjmed.2015.11.001"},{"key":"10.5826\/dpc.1503a5333_ref89","doi-asserted-by":"crossref","unstructured":"De Jesus MM, Santiago JS, Trinidad CV, et al. Autologous adipose-derived mesenchymal stromal cells for the treatment of psoriasis vulgaris and psoriatic arthritis: a case report. Cell Transplantation. 2016;25(11):2063\u20132069. DOI:10.3727\/096368916X691998","DOI":"10.3727\/096368916X691998"},{"key":"10.5826\/dpc.1503a5333_ref90","doi-asserted-by":"crossref","unstructured":"Wang SG, Hsu NC, Wang SM, Wang FN. Successful treatment of plaque psoriasis with allogeneic gingival mesenchymal stem cells: a case study. Case reports in dermatological medicine. 2020;2020DOI:10.1155\/2020\/4617520","DOI":"10.1155\/2020\/4617520"},{"key":"10.5826\/dpc.1503a5333_ref91","doi-asserted-by":"crossref","unstructured":"Chen M, Peng J, Xie Q, et al. Mesenchymal stem cells alleviate moderate-to-severe psoriasis by reducing the production of type I interferon (IFN-I) by plasmacytoid dendritic cells (pDCs). Stem cells international. 2019;2019DOI:10.1155\/2019\/6961052","DOI":"10.1155\/2019\/6961052"}],"container-title":["Dermatology Practical &amp; Conceptual"],"original-title":[],"link":[{"URL":"https:\/\/dpcj.org\/index.php\/dpc\/article\/download\/5333\/3141","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dpcj.org\/index.php\/dpc\/article\/download\/5333\/3559","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dpcj.org\/index.php\/dpc\/article\/download\/5333\/3141","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T10:18:15Z","timestamp":1765275495000},"score":1,"resource":{"primary":{"URL":"https:\/\/dpcj.org\/index.php\/dpc\/article\/view\/5333"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,31]]},"references-count":91,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.5826\/dpc.1503a5333","relation":{"has-manifestation":[{"id-type":"other","id":"1-80-5333-g3141","asserted-by":"subject"},{"id-type":"other","id":"1-80-5333-g3559","asserted-by":"subject"}],"is-part-of":[{"id-type":"doi","id":"10.5826\/dpc.1503a%a","asserted-by":"subject"}]},"ISSN":["2160-9381"],"issn-type":[{"type":"electronic","value":"2160-9381"}],"subject":[],"published":{"date-parts":[[2025,7,31]]},"article-number":"2"}}